• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

    3/4/24 4:24:14 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TVGN alert in real time by email
    SC 13G 1 tevogen13g.htm



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. )*

    Tevogen Bio Holdings Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     

     88165K101
    (CUSIP Number)
     
    February 14, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☐
    Rule 13d-1(b)
     
    ☒
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    Persons who respond to the collection of information contained
    in this form are not required to respond unless the form
    displays a currently valid OMB control number.

    CUSIP No.
    88165K101
    13G
     
     
     
    1
    NAMES OF REPORTING PERSONS
     
     
     
     
     
    Manmohan Patel
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a) ☐
     

    (b) ☐
     

    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    646,412
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    8,628,077
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    646,412
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    8,628,077
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,274,489
     
     
     
     
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     ☐

           
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.6%(1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON*
     
     
    IN
     
     
     
     

    (1)
    Calculated based on 164,614,418 shares of Common Stock outstanding as of Febuary 22, 2024 as disclosed in the Schedule 13D filed by Ryan H. Saadi on February 22, 2024.





    CUSIP No.
    88165K101
    13G
     
     

     Item 1(a)
     Name of Issuer:
     
     
     
    The name of the issuer is Tevogen Bio Holdings Inc. (the “Issuer”).
     
     
    Item 1(b)
    Address of Issuer's Principal Executive Offices:
     
     
     
    15 Independence Boulevard, Suite #410, Warren, New Jersey 07059.
     
     
    Item 2(a)
    Name of Person Filing:
     
     
     
    Manmohan Patel
     
     
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:
     
     
     
    5 Jennie Court, Cedar Grove, NJ 07009
     
     
    Item 2(c)  Citizenship:
       
     
    United States 
       
    Item 2(d)
    Title of Class of Securities:
     
     
     
    Common Stock
     
     
    Item 2(e)
    CUSIP No.:
     
     
     
    88165K101
     
     
    Item 3
    If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
     (a) ☐ 
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     (b) ☐ 
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     (c) ☐ 
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     (d) ☐ 
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     (e) ☐ 
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
     (f) ☐ 
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
     (g) ☐ 
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
     (h) ☐ 
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     (i) ☐ 
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     (j) ☐ 
    A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
     (k) ☐ 
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .



    Item 4
    Ownership:


    Tevogen Bio Holdings Inc.

     
    (a)
      Amount beneficially owned: 9,274,489
     
     
    (b)
      Percent of class:  5.6%
     
     
    (c)
      Number of shares as to which such person has: 
     
     
    (i)
      Sole power to vote or direct the vote:  646,412
     
     
     
    (ii)
      Shared power to vote or direct the vote: 8,628,077
     
     
     
    (iii)
      Sole power to dispose or direct the disposition: 646,412
     
     
     
    (iv)
      Shared power to dispose or direct the disposition: 8,628,077

    Item 5
    Ownership of Five Percent or Less of a Class:
       


     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.
     
    Item 6 Ownership of More Than Five Percent on Behalf of Another Person:


     
     Not applicable.


    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
     
     
     
    Not applicable.
     
     
    Item 8
    Identification and Classification of Members of the Group:
     
     
     
    Not applicable.
     
     
    Item 9
    Notice of Dissolution of Group:
     
     
     
    Not applicable.
     
     
    Item 10
    Certification:
     
     
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date: March 4, 2024

           Manmohan Patel  
             
           /s/ Manmohan Patel  
           Manmohan Patel  

       


     
     



    Get the next $TVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TVGN

    DatePrice TargetRatingAnalyst
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/13/24 4:30:24 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/7/24 4:29:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    SEC Filings

    See more
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      6/27/25 5:26:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Tevogen Bio Holdings Inc.

      EFFECT - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      6/27/25 12:15:22 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      6/23/25 5:09:36 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Saadi Ryan H. sold $1,768,993 worth of shares (1,438,206 units at $1.23), decreasing direct ownership by 1% to 116,814,453 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/9/25 7:13:44 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Flomenberg Neal sold $253,935 worth of shares (232,968 units at $1.09), decreasing direct ownership by 6% to 3,595,608 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/14/25 9:02:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Flomenberg Neal sold $231,734 worth of shares (211,909 units at $1.09), decreasing direct ownership by 5% to 3,828,576 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      3/11/25 8:52:08 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care